XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing therapies for gout, progressive kidney disease, and other disorders linked to elevated uric acid and abnormal purine metabolism. Its current pipeline includes programs for gout, autosomal dominant polycystic kidney disease, acute kidney injury associated with respiratory virus infections, and type 2 diabetic nephropathy. The company’s research centers on uric acid-lowering and xanthine oxidase-targeted approaches designed to address conditions ranging from rare kidney diseases to broader metabolic and renal disorders. Based in Calgary, Canada, XORTX Therapeutics Inc. operates as a biotechnology and pharmaceutical developer with an emphasis on advancing drug candidates through clinical development and commercialization in specialized disease areas.
Website3710 – 33rd Street NW
Calgary, AB, T2L 2M1
Canada
Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica
● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the launch of production of drug material and tablet manufacturing to support t
Detailed price information for Xortx Therapeutics Inc (XRTX-Q) from The Globe and Mail including charting and trades.
CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ('XORTX ' or the “Company ”) announces that, following completion o...
CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term
Investors talking about XRTX also mention
What share of all stock conversation is about XRTX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% +0 | 0% +0 | 0% 0 |
Of the messages about XRTX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 100% +25 | 90.91% | 87.01% -4.24 | ||
| Bearish | — | 0% -25 | 9.09% | 12.99% +4.24 |
Of the messages about XRTX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | 21.13% | 31.46% | 31.22% | ||
| Analysts | — | 39.44% | 31.46% | 18.03% | ||
| Technical Analysis | — | 0% | 5.62% | 32.05% | ||
| Macro | — | 39.44% | 31.46% | 18.03% | ||
| Controversies | — | 0% | 0% | 0.67% | ||
| Earnings | — | 0% | 0% | 0% |
Of the messages about XRTX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 6.29% | 6.01% | 30.89% | ||
| Newcomers | 100% | 93.71% | 93.99% | 69.11% |